Semaglutide During Menopause

Wegovy is a semaglutide brand with an adult weight-management indication. Its current US prescribing information includes both weekly injections and daily tablets. Other semaglutide brands have their own approved uses and instructions. The active ingredient alone does not tell you the appropriate dose or indication.

For weight management, the usual adult eligibility threshold is a BMI of at least 30, or at least 27 with a weight-related condition, such as high blood pressure or type 2 diabetes. A clinician also reviews previous treatment, other medicines, pregnancy plans, and conditions that affect safety.

Menopause does not have a separate semaglutide dosing schedule. If your main concern is a changing waist without a qualifying weight-related indication, a review of body composition, activity, nutrition, and metabolic health may be more useful than a prescription.

The Wegovy label reports results from different adult trials. The examples below used nutrition and activity advice alongside treatment. They included women and men with obesity, or overweight with a qualifying condition, and excluded type 2 diabetes.

These were separate studies with different durations and participants, so the table cannot establish which formulation works better. The figures also do not predict your result. In a separate trial of injectable semaglutide involving adults with type 2 diabetes, average loss was lower.

A small 2024 study specifically examined postmenopausal women receiving semaglutide. Women using hormone therapy lost more weight on average, but treatment groups were not randomly assigned and differed in some characteristics. The finding does not establish that starting HRT improves semaglutide results.

Wegovy injection is taken weekly. Treatment starts at a low dose and increases in stages to help with tolerance. The appropriate maintenance dose depends on the indication and response. The current label also includes a higher-dose injectable option for selected adults; the commonly quoted 2.4 mg dose is not the entire prescribing range.

Wegovy tablets are taken every morning on an empty stomach, with up to four ounces of water. Swallow the tablet whole and wait at least 30 minutes before food, drink, or other oral medicines. Tablet doses increase on a different schedule from injection doses. The milligram amounts are not interchangeable.

This timing deserves attention if you take morning thyroid medication. Oral semaglutide increased levothyroxine exposure in an interaction study reported in the label. Ask the prescriber or pharmacist to set out a workable schedule and decide whether additional monitoring is needed.

Obtain written instructions for missed doses, storage, and any formulation change. Do not add another semaglutide or GLP-1 medicine to the prescription.

Early fullness and nausea can reduce intake more than expected. If breakfast disappears, lunch becomes a few bites, and dinner is difficult, tell the care team. Repeatedly struggling to eat or drink calls for a treatment review and help with nutrition.

Include protein foods in meals that you can tolerate, alongside other foods that provide energy, fiber, and nutrients. Kidney disease or another dietary restriction may change that advice. A dietitian can help with portions and meal frequency while symptoms are being assessed.

Follow strength and everyday function as weight changes. Difficulty carrying groceries, getting up from a chair, or completing a usual walk deserves discussion. Adult activity guidance includes muscle-strengthening work on at least two days each week, adapted to your ability.

• Wegovy is contraindicated with a personal or family history of medullary thyroid cancer, MEN 2, or a previous serious allergic reaction to semaglutide.
• Review pancreatitis, gallbladder disease, severe gastroparesis, kidney problems, and diabetic eye disease before treatment.
• Insulin or sulfonylurea treatment may need adjustment to reduce low blood glucose risk.
• Tell an anesthesia team about semaglutide before a procedure because delayed stomach emptying can increase aspiration concerns.

The boxed thyroid warning is based on tumors in rodents; the relevance to humans remains unknown. If your history simply says 'thyroid disease,' bring the actual diagnosis. Different thyroid conditions have different implications.

For weight treatment, stop Wegovy when pregnancy is recognized and at least two months before a planned pregnancy. Ovulation can still occur during perimenopause, so contraception and pregnancy plans should be reviewed even when periods are irregular.

Discuss which outcomes matter: weight trend, blood pressure, glucose, physical function, and tolerability. If hot flashes or sleep disruption continue, assess those separately. A change in weight does not tell you whether menopause symptoms are adequately treated.

Weight medication may be continued long term when effective and tolerable; regain can occur after stopping. Ask how follow-up, refills, costs, and interruptions will be handled. If a compounded product is offered, confirm the formulation and why an FDA-approved option cannot meet the medical need. Compounded semaglutide does not undergo FDA approval review.